Copyright
©The Author(s) 2020.
World J Stem Cells. Oct 26, 2020; 12(10): 1080-1096
Published online Oct 26, 2020. doi: 10.4252/wjsc.v12.i10.1080
Published online Oct 26, 2020. doi: 10.4252/wjsc.v12.i10.1080
Cell type | Medium | Supplements | Initial density | Protocol duration | Note | Ref. |
“MSC-like” differentiated cell types | ||||||
Adipogenic cells | DMEM | Dexamethasone 1 µmol/L, isobutyl-1 methylxanthine 500 µmol/L, indomethacin 66 µmol/L, hydrocortisone 500 µmol/L | 14000 cells/cm² | 24 d | 2 d in DMEM without supplement before differentiation | [15] |
DMEM low glucose | Dexamethasone 1 µmol/L, isobutyl-1 methylxanthine 500 µmol/L, indomethacin 100 µmol/L, insulin 10 µg/mL | 20000 cells/cm² | 28 d | / | [30] | |
Specific adipogenic medium | FBS (optional) | 1000 to 5000 cells/cm² | 14 d | / | [13,22,23,33,39] | |
Specific adipogenic medium | NA | 80% of confluency | 14 d | / | [24] | |
Chondrogenic cells | DMEM/Ham's F12 | Fetal calf serum 10%, insulin 6 µg/mL, ascorbic acid 2P 0.2 mmol/L, TGF-b1 10 ng/mL | 1500 cells/cm² | 28 d | / | [15] |
Specific chondrogenic medium | NA | 50000 cells/cm² | 28 d | / | [22,24] | |
Specific chondrogenic medium | NA | 300000 cells to 1000000 cells | 28 d | Cell aggregation in conical polypropylene tube before differentiation | [23] | |
Osteogenic cells | DMEM low glucose | Dexamethasone 10-100 nmol/L, ascorbate2-phosphate 50-1500 µmol/L, glycerophosphate 10 mmol/L, FCS 10%, Vit D3 10 nmol/L (optional) | 1500 to 4000 cells/cm² | 28 d | / | [15,30] |
DMEM low glucose | FBS + osteogenic supplement | 4000 cells/cm² | 28 d | / | [23] | |
Specific osteogenic medium | NA | 1000 cells/ cm² | 28 d | / | [39] | |
Specific osteogenic medium | NA | 80% confluency at P4 | 14 d to 21 d | / | [22,24,33] | |
Other cell types | ||||||
Endothelial cells | EBM-2 | VEGF 50 ng/mL + FBS (optional) | 3000 to 5000 cells/cm² | 9 d to 14 d | Coating with fibronectin + 2 d of preculture | [23,31,32] |
Microbeads | VEGF | 1000 cells/cm² | 14 d | MD | [35] | |
Neuronal cells | Specific nerve induction medium | NA | 6000 cells/cm² | 2 d | Pre-culture with DMEM + 20% FBS + 10 ng/mL bFGF 24 h | [23] |
DMEM F12 | hEGF 20 ng/mL, bFGF 40 ng/mL, B27 2%, NEAA 1%, l-glutamine 1%, insulin-transferrin-selenite 1%. | 20%-30% of confluency | 12 d | Coating: Polystyrene | [22] | |
NeuroCult NS-A differentiation kit | NA | 100000 cells/cm² | 7 d | Preculture | [24] | |
NM3 basic neuronal induction medium | Y27632 10 μmol/L, A8301 5 μmol/L, CHIR99021 3 μmol/L, TTNPB 1 μmol/L, forskolin5 μmol/L, valproic acid 0.5 mmol/L, sodium butyrate 0.1 mmol/L | MD | MD | Coating with Matrigel and preculture (2 d) | [37] | |
Skeletal myogenic cells | DMEM | Skeletal supplement + SVF 10%, Horse serum 5%, hydrocortisone 50 µmol/L, dexamethasone 0,1 µmol/L | MD | 28 d | / | [23] |
Conditioned medium | NA | MD | 28 d | 12 h of culture of medium with skeletal myogenic cells | [23] | |
Conditioned medium | NA | 80% confluency | 14 d | Culture of medium with skeletal myogenic cells | [24] | |
Smooth muscle cells | DMEM + EFM (1:1) | FBS, TGF-β1 (2.5 ng/mL), PDG-BB (2.5 to 5 ng/mL) | 1000 to 2000 cells/cm² | 14 d | / | [12,19,23,34,36] |
Renal differentiation | ||||||
Podocytes | VRAD: DMEMF12 | FBS 10%, vitamin D3 100 nmol/L, retinoic acid 100 µmol/L | MD | 48 h | MD | [14] |
Tubular cells | REGM | Hepatocyte growth factor 50 ng/mL | MD | 21 d | MD | [14] |
Urothelium cells | KFSM + EFM (1:1) | FBS 2%, EGF 30 ng/mL | 3000 cell/cm² | 14 d | MD | [36] |
KFSM | FBS 2%, EGF 30 ng/mL | 3000 cell/cm² | 14 d | MD | [34] | |
KFSM + EFM (4:1) | FBS 2%, EGF 30 ng/mL | 3000 cells/cm² | 14 d | / | [36] | |
DMEM + KFSM (4:1) | FBS 8%, EGF 30 ng/mL | 1,000 cells/cm² | 14 d | / | [19] | |
Conditioned medium from urothelial cells 8 h + EFM + KFSM (1:1) | EGF 30 ng/mL | 50000 cells/cm² | 7 to 21 d | Dynamic culture | [21] | |
Conditioned medium of smooth muscle cells 12 h + KFSM (1:1) | NA | 50000 cells/cm² | 7 to 21 d | Dynamic culture | [21] |
- Citation: Burdeyron P, Giraud S, Hauet T, Steichen C. Urine-derived stem/progenitor cells: A focus on their characterization and potential. World J Stem Cells 2020; 12(10): 1080-1096
- URL: https://www.wjgnet.com/1948-0210/full/v12/i10/1080.htm
- DOI: https://dx.doi.org/10.4252/wjsc.v12.i10.1080